Comparison of GW433908/Ritonavir to Nelfinavir When Used With Abacavir and Lamivudine in Patients That Have Not Taken Antiretroviral Drugs
HIV Infections
About this trial
This is an interventional treatment trial for HIV Infections focused on measuring HIV-1, Drug Therapy, Combination, HIV Protease Inhibitors, Ritonavir, Lamivudine, Nelfinavir, Reverse Transcriptase Inhibitors, Anti-HIV Agents, abacavir
Eligibility Criteria
Inclusion Criteria Patients may be eligible for this study if they: Are at least 13 years old (consent of parent or guardian needed if under 18). Agree to use a proven barrier method of birth control (e.g., spermicide plus condom) during the study period (hormonal birth control will not be accepted), if able to have children. Have received less than 4 weeks treatment with any nucleoside reverse transcriptase inhibitor (NRTI) and have never received any nonnucleoside reverse transcriptase inhibitor (NNRTI) or protease inhibitor (PI). Mothers who have previously received 1 dose of the NNRTI nevirapine during pregnancy for prevention of mother-to-child HIV transmission are permitted to enter the study. Have a viral load (amount of HIV in the blood) of 1,000 copies/ml or more. Exclusion Criteria Patients will not be eligible for this study if they: Abuse drugs or alcohol in a way that would interfere with study requirements. Patients who are stable on methadone will be considered for the study. Have an active/acute CDC Category C event. Are unable to absorb or take medicines by mouth. Are pregnant or breast-feeding. Have a serious medical condition (such as diabetes, heart problem, hepatitis) that might affect the safety of the patient. Have had pancreatitis or hepatitis within the last 6 months. Have been treated with radiation or chemotherapy within 28 days before the study drug will be taken, or will have the need for these during the study. Have taken drugs that affect the immune system (such as corticosteroids, interleukins, interferons) or that have anti-HIV activity (such as hydroxyurea or foscarnet) within 28 days before the study drug will be taken. Have received an HIV vaccine within 3 months before the study drug will be taken. Have received certain other drugs within 28 days before the study drug will be taken, or think that they will be needed during the study. Have received experimental treatments. Have allergies which might interfere with the study, in the opinion of the doctor.
Sites / Locations
- Orange County Ctr for Special Immunology
- AIDS Healthcare Foundation
- LAGLC
- Kaiser Hospital
- Park Ctr for Health / Keith Vrhel
- AIDS Research Alliance
- Dupont Circle Physicians Group
- Infectious Disease Consultants
- CRI of South Florida
- Therafirst Med Ctr
- Gary Richmond MD
- Univ of Miami Dept of Medicine
- Specialty Med Care Ctrs of South Florida Inc
- Infectious Diseases Associates
- Jeffrey Levenson
- Infectious Disease Research Inst
- AIDS Research Consortium of Atlanta
- Med College of Georgia
- SMO USA
- Indiana Univ Med School
- Brigham and Women's Hosp
- Hawthorne Med Associates / PAACA
- Abbott-Northwestern Hosp / Clinic 42
- Southampton Healthcare Inc
- VAMC New Jersey Healthcare System
- North Jersey Community Research Initiative
- Bronx Veterans Affairs Med Ctr
- SUNY / Erie County Med Ctr at Buffalo
- North Shore Univ Hosp
- St Lukes - Roosevelt Hosp Ctr
- Univ of Cincinnati / Holmes Hosp
- Milton S Hershey Med Ctr
- Hahnemann Univ Hosp
- Burnside Clinic
- Methodist Healthcare
- Nicholas Bellos
- Joseph C Gathe